Skip to main content



Local Cdiff information for Arizona

Arizona

Learn about C. diff providers, regulation, clinical trials, and advocacy efforts in Arizona.



Local Cdiff information for Arizona

Arizona

Learn about C. diff providers, regulation, clinical trials, and advocacy efforts in Arizona.

Providers

Dr. Andrew Weinberg, DO

District Medical Group
8088 W Whitney Dr
Peoria, 85345
(833) 855-9973
FMT Provider: Yes
VISIT WEBSITE >

Dr. Robert Orenstein, DO

Associate Professor of Medicine
Mayo Clinic
5777 E Mayo Blvd
Phoenix, 85054
480-342-2000
FMT Provider: Yes
VISIT WEBSITE >

Regulation

C. diff Infections

Total Reported Cases: 1,235
Hospital Onset: 1,235
Community Onset: Not reported
Related Deaths: Not reported

Available Reports

Annual Progress based on SIR: 1
CDC STATE PROGRESS REPORT >
STATE REPORTING >

State Reporting Laws

Data Submission Required: No
Data Publicly Available: No
Data Validated: No
Facility-specific Data Publicly Reported: No
LTC Facility Submission Required: No
LTC Facility Data Publicly Reported: No
Law/Regulation: Not available
STATUTE >

State Contact

Eugene K. Livar III, MD
Healthcare Associated Infections Program Manager
Arizona Department of Health Services
Office of Infectious Disease Services
150 N. 18th Ave., Suite 140
Phoenix, 85007
(602) 364-3522
EMAIL EUGENE K. LIVAR III, MD 

Title of my state update

This is my update here. Another update here.

CLINICAL TRIALS

OpTION

Official Title: CSP #596 – Optimal Treatment for Recurrent Clostridium Difficile Infection
Trial No. NCT02667418
Type: Interventional
Recruitment: Recruiting
Sponsor: VA Office of Research and Development
Contact: Michelle Johnson
(708) 202-8387 ext 27001
EMAIL
Gender: All
Age: 18 Years and older

FMT National Registry

Official Title: Fecal Microbiota Transplant National Registry
Trial No. NCT03325855
Type: Observational
Recruitment: Recruiting
Sponsor: American Gastroenterological Association
Contact: Sonya Serra, MSc
301-941-2616
EMAIL
Gender: All
Age: All ages

RESTORATiVE303

Official Title: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection
Trial No. NCT06237452
Type: Interventional
Recruitment: Recruiting
Sponsor: Vedanta Biosciences, Inc
Contact: Mary Garfield
EMAIL >
Gender: All
Age: 12 Years and older
Vedanta Biosciences has teamed up with Science37 to provide a site-less, decentralized approach. This means the study can be done remotely and the product comes to you, in your home. This allows applicants who are not near a study site or unable to travel to participate and receive treatment. You can sign up for the decentralized study here.

To Understand the Safety and Effects of a C. Difficile Vaccine

Official Title: A Phase 1/2 Randomized Study to Evaluate the Safety, Tolerability, Immunogenicity, and Immunopersistence of a Clostridioides Difficile Vaccine Administered in a 2-Dose Regimen With Novel Adjuvants in Healthy Adults
Trial No. NCT05805826
Type: Interventional
Recruitment: Recruiting
Sponsor: Pfizer
Contact: Pfizer CT.gov Call Center
EMAIL >
Gender: All
Age: 65 Years and older